Document Detail


Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
MedLine Citation:
PMID:  23332165     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Bioabsorbable vascular scaffolds were developed to overcome limitations of permanent bare-metal or drug-eluting coronary stents-ie, stent thrombosis (despite prolonged dual antiplatelet therapy), the life-long presence of a caged vessel segment that does not allow vasomotion or remodelling, and chronic vessel wall inflammation. We assessed the safety and performance of a new magnesium-based paclitaxel-eluting absorbable metal scaffold in symptomatic patients with de-novo coronary lesions. METHODS: We did a prospective, multicentre, first-in-man trial (BIOSOLVE-1) of the drug-eluting absorbable metal scaffold (DREAMS). 46 patients with 47 lesions were enrolled at five European centres. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation, at 6 and 12 months. Clinical follow-up was scheduled at 1, 6, 12, 24, and 36 months. Patients were consecutively assigned to angiographic and intravascular ultrasonographic follow-up at 6 months or 12 months. Optical coherence tomography was done in some patients. All patients were recommended to take dual antiplatelet therapy for at least 12 months. This trial is registered with ClinicalTrials.gov, number NCT01168830. FINDINGS: Overall device and procedural success was 100%. Two of 46 (4%) patients had target lesion failure at 6 months (both clinically driven target lesion revascularisations), which rose to three of 43 (7%) at 12 months (one periprocedural target vessel myocardial infarction occurred during angiography at the 12 month follow-up visit). We noted no cardiac death or scaffold thrombosis. INTERPRETATION: Our results show feasibility, a good safety profile, and promising clinical and angiographic performance results up to 12 months for DREAMS. Our promising clinical results show that absorbable metal scaffolds might be an alternative to polymeric absorbable scaffolds. FUNDING: Biotronik.
Authors:
Michael Haude; Raimund Erbel; Paul Erne; Stefan Verheye; Hubertus Degen; Dirk Böse; Paul Vermeersch; Inge Wijnbergen; Neil Weissman; Francesco Prati; Ron Waksman; Jacques Koolen
Related Documents :
25104055 - Biatrial ablation versus limited right atrial ablation for atrial fibrillation associat...
15321185 - Acupressure for intrathecal narcotic-induced nausea and vomiting after caesarean section.
24526505 - Impact of drug-eluting stents with different coating strategies on stent thrombosis: a ...
24216285 - A prospective randomized trial of everolimus-eluting stents versus bare metal stents in...
9500295 - Alveolo-capillary protein permeability and lung function in patients with late pulmonar...
21652145 - Three-year postoperative ultrasensitive prostate-specific antigen following open radica...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-14
Journal Detail:
Title:  Lancet     Volume:  -     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Affiliation:
Medical Clinic I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany. Electronic address: mhaude@lukasneuss.de.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Professional collegiality and peer monitoring among nursing staff: an ethnographic study.
Next Document:  Initial staging for squamous cell carcinoma of the mouth, larynx and pharynx (except nasopharynx). P...